MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer

201993 citationsJournal Articlehybrid Open Access

Authors

Nicholas G. Nickols · University of California, Los Angeles

Ramin Nazarian · University of California, Los Angeles

Shuang G. Zhao · University of Michigan

Victor M. Tan · Johnson University

Vladislav Uzunangelov · University of California, Santa Cruz

Zheng Xia · Oregon Health & Science University

Robert Baertsch

Abstract

We conclude that pharmacologic targeting of the MEK/ERK pathway may be a viable treatment strategy for patients with refractory metastatic prostate cancer. An ongoing Phase II trial tests this hypothesis.

Topics & Keywords

Prostate Cancer Treatment and Research Melanoma and MAPK Pathways Cancer Mechanisms and Therapy

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Prostate Cancer and Prostatic Diseases

Volume 22, Issue 4, pp. 531-538

DOI: 10.1038/s41391-019-0134-5

Field-Weighted Citation Impact: 8.51